

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
06275/004001

SERIAL NO.

08/265,237 08/736267

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Kjell G.E. Bäckström et al.FILING DATE
June 23, 1994

GROUP

1811-1817

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BP	AA	4 7 4 6 5 0 8	5/24/88	Carey et al.	424	88	
BP	AB	4 9 5 9 3 5 8	9/28/88	Carey et al.	514	171	
BP	AC	4 5 4 8 9 2 2	10/22/85	Carey et al.	514	4	
BP	AD	4 6 6 8 2 1 8	5/26/87	Virtanen	604	58	
BP	AE	4 5 2 4 7 6 9	6/25/85	Wetterlin	428	203-15	
BP	AF	4 5 3 4 3 4 5	8/13/85	Wetterlin	428	203-15	
BP	AG	4 9 0 7 5 8 3	3/13/90	Wetterlin et al.	428	203-15	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BP	AH	WO 88/09163	01/12/88	PCT				
BP	AI	0 272 097	22/06/88	Europe				
BP	AJ	1 527 605	04/10/76	Great Britain				
BP	AK	0 455 463	06/11/91	Europe				
BP	AL	8007820-7	86-11-17	Sweden				
BP	AM	0 225 189	28-11-86	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

BP	AN	Allenby et al., The Absorption of Insulin Across the Respiratory Tract of the Guinea-Pig (U), The Aerosol Society, Fourth Annual Conference 1990, pp. 129-134
BP	AO	Aungst and Rogers, Comparison of the Effects of Various Transmucosal Absorption Promoters on Buccal Insulin Delivery, Int. J. Pharm. (Netherlands), 1989, 53/3, 227-235
BP	AP	Björk, Starch Microspheres as a Nasal Delivery System for Drugs, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 103, 1993
BP	AQ	Björk and Edman, Degradable Starch Microspheres as a Nasal Delivery System for Insulin, Int. J. Pharm. 47:233-238, 1988
BP	AR	Brange et al., Monomeric Insulins and Their Experimental and Clinical Implications, Diabetes Care 13:923-954, 1990
BP	AS	Edman and Björk, Routes of Delivery: Case Studies, Advanced Drug Delivery Reviews 8:165-177, 1992

EXAMINER

Benet Prickril

DATE CONSIDERED

5/1/95

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
06275/004001SERIAL NO.
08/265,237INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Kjell G.E. Bäckström et al.

FILING DATE

June 23, 1994

GROUP

1811

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

BP	BA	Igawa et al., Effect of Absorption Promoters in Intranasal Administration of Human Fibroblast Interferon as a Powder Dosage Form in Rabbits, Chem. Pharm. Bull. 37:418-421, 1989
BP	BB	Komada et al., Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung, J. Pharm. Sci. 83:863-867, 1994
BP	BC	Lasker, The Diabetes Control and Complications Trial, N. Engl. J. Med. 329:1035-1036, 1993
BP	BD	Laube et al., Preliminary Study of the Efficacy of Insulin Aerosol Delivered by Oral Inhalation in Diabetic Patients, JAMA 269:2106-2109, 1993
BP	BE	Lee et al., Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ratio, J. Pharm. Sci. 80:725-729, 1991
BP	BF	Mishima et al., Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats, J. Pharma -Dyn. 10:624-631, 1987
BP	BG	Morita et al., Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights, Biol. Pharm. Bull. 16:269-262, 1993
BP	BH	Nagai et al., Powder Dosage Form of Insulin for Nasal Administration, J. Controlled Release 1:15-22, 1984
BP	BI	"Diabetes Mellitus", Ch. VI in Scientific American Medicine, Scientific American, Inc., April 1993
BP	BJ	The Diabetes Control and Complications Trial Research Group, The Effect of Intensive Treatment of Diabetes on the Development...Complications in Insulin-Dependent Diabetes Mellitus, N. Engl. J. Med. 329:977-86, 1993
BP	BK	Pontiroli et al., Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: a Comparison of Powders and Spray Solutions and of Different Enhancing Agents, Eur. J. Clin. Pharmacol. 37:427-430, 1989
BP	BL	Schipper et al., Nasal Insulin Delivery with Dimethyl- β -Cyclodextrin as an Absorption Enhancer in Rabbits: Powder More Effective than Liquid Formulations, Pharmaceutical Research 10:682-686, 1993
BP	BM	Selam and Charles, Devices for Insulin Administration, Diabetes Care 13:955-979, 1990
BP	BN	Touitou and Rubenstein, Targeted Enteral Delivery of Insulin to Rats, Int. J. Pharm. (Amst.), 30(2-3), 1986, 95-100
BP	BO	Wigley et al., Insulin Across Respiratory Mucosae by Aerosol Delivery, Diabetes 20:552-556, 1971
BP	BP	Zinman, Medical Intelligence - The Physiologic Replacement of Insulin, N. Engl. J. Med. 321:363-370, 1989

EXAMINER

Benet Poickri

DATE CONSIDERED

5/1/95

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.